Abstract: A method for controlling snails in aqueous systems which involves treating aqueous systems which contain snails or which are prone to snail infestation with an effective amount of a water-soluble dialkyl diallyl quaternary ammonium polymer (polyquat) is disclosed. A preferred polymer is a poly(quaternary ammonium) compound having a recurring structure (DMDAAX−) resulting from the polymerization of monomeric dimethyl diallyl ammonium X−, wherein X− is any suitable anion.

Abstract: Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.

Abstract: Novel diol blends are disclosed. The blends are comprised of an aromatic diol portion derived from dihydric phenol and an aliphatic diol portion in a ratio of aromatic to aliphatic of 5:95 to 95:5. The aromatic portion is the reaction product of a dihydric phenol and one or more alkylene carbonates using a stoichiometric excess of carbonate. Methods for preparing these diol blends are also disclosed, as are methods for using these compounds in the preparation of cast elastomers. Cast elastomers prepared from these blends are also disclosed; the elastomers have physical and mechanical properties that make them appropriate for use in many demanding applications.

Abstract: Novel sulfatase inhibitor/estrogen receptor blocker compounds useful in the treatment of estrogen dependent illnesses are disclosed. The compounds generally comprise a sulfamate moiety and an aromatic, estrogen receptor blocker moiety. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of an estrogen-dependent disease are also disclosed.

Abstract: Sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.

Abstract: A method of inducing apoptosis in a cell. The method includes providing an impenetrable and nonmetabolizable material, such as paraffin or agar, and introducing the cell into a contacting relationship with the material. The method also includes providing a substrate and coating the substrate with the impenetrable and nonmetabolizable material.

Abstract: Novel sulfatase inhibitor/estrogen receptor blocker compounds useful in the treatment of estrogen dependent illnesses are disclosed. The compounds generally comprise a sulfamate moiety and an aromatic, estrogen receptor blocker moiety. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of an estrogen-dependent disease are also disclosed.

Abstract: A time release orally administrable drug containing product comprising a core, a drug layer attached to the core, and first and second coating layers is disclosed. The first coating layer is directly adjacent to the drug layer, and has a limited permeability to water. The second coating layer is directly adjacent to the first coating, and is more permeable to water than the first layer. A method for using this drug in the treatment of a patient is also disclosed.

Abstract: The invention also discloses compounds and pharmaceutically acceptable salts having the generic formula (2) ##STR1## wherein X and Y may be the same or different and are selected from the group consisting of OH and NH.sub.2 ; wherein Z is one of either nitrogen or carbon and Q is one of either nitrogen or carbon but when Z equal nitrogen, Q does not equal nitrogen and when Q equals nitrogen, Z does not equal nitrogen; wherein A is selected from the group consisting of nitrogen, carbon and sulfur and B equals carbon when A is selected from the group consisting of sulfur, carbon, and nitrogen, B equals nitrogen when A equals carbon and B equals sulfur when A equals carbon; wherein R.sub.3 is one of either hydrogen or methyl except where Z is nitrogen wherein R.sub.3 is zero; wherein R.sub.4 is one of either a hydrogen or a first lower alkyl group except when A equals sulfur wherein R.sub.4 is zero; wherein R.sub.

Abstract: This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed. More specifically, furo[2,3-d[pyrimidines are disclosed.

Abstract: This invention discloses a durable catalyst for internal combustion engine or power plant exhaust gas purification which is comprised of a zeolite as the support and Fe (II) base-exchanged cation as the active component for the NO.sub.x selective catalytic reduction (SCR). It has stable activity with up to 20% H.sub.2 O and up to 250 ppm SO.sub.2 and combinations thereof over many hours in the exhaust stream. It is resistant to temperature excursions up to about 1,000.degree. C. The method of producing this catalyst preferably comprises ion-exchanging the zeolite with Fe (II) in an aqueous solution of iron (II) oxalate, iron (II) citrate or iron (II) formate, or a mixture of oxalic acid, citric acid/salts, formic acid/salts, 2,3,4,5,6-pentahydroxyl caproic acid/salts and iron (II) salts, for example, sulfate, nitrate, chloride, carboxylate, chloride acetate, phosphate and carbonate, in the pH range from 3 to 13 under anaerobic conditions.

Abstract: A chromogenic receptor comprises a self-assembled chromogenic compound having at least one intrinsic binding site. The chromogenic compound is characterized by the property of producing a reversible color change responsive to binding a target substrate to the receptor. The chromogenic compound has a transition metal ion and at least one ligand bound to the transition metal ion. The ligand is selected from the group consisting of substituted phenanthroline, substituted 2,2'-bipyridine and substituted 2,2':6',2"-terpyridine. The transition metal is selected from the group consisting of Cu(I), Cu(II), Ag(I), Ni(II), Fe(II), Fe(III), Ru(II), Co(III), and Os(II). Self-assembly can be effected in the presence of Cu(I) to form receptors for dicarboxylic acids, carbohydrate, amino acids, steroids and pyrophosphates. The receptors are characterized by the formation of a 2:1 complex of the target substrate with the receptor producing a visible color change from orange to red and a measurable change in its luminescence.

Abstract: A support device for supporting and/or immobilizing the articulated or non-articulated areas of an anatomy. The support device comprises a flexible member having connecting ends, intermediate portions, a central portion, a pad member containing a viscous substance in the central portion, and a permanently deformable sheet. The deformable sheet is deformed in situ and is insertable into the central portion adjacent to the pad member and outwardly thereof so that the pad member is positioned toward the anatomy and conforms to the shape of the deformable sheet and provides comfort to the user. Slots are provided in the flexible member for receiving the deformable sheet and for optionally receiving a chin support which in conjunction with an occipital support which is supported by the deformable sheet enables the support device to be used as a cervical brace. The deformable sheet may be a one-piece member or it may be several interconnected curved members, and it may be a simple curve or a compound curve.

Abstract: This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed. More specifically, the compounds include pyrrolo?2,3-d!pyrimidines and furo?2,3-d!pyrimides and derivatives thereof.

Abstract: Peptidyl prodrugs of therapeutic agents having an activating function are sclosed. These therapeutic agents having activating functions include those having an amino, thiol, or hydroxyl function. Methods of making and using these prodrugs are also disclosed.

Abstract: The present invention relates to prophylactic and therapeutic methods of anti-tumor immunization. These methods are based on cross-priming a mammalian host to natural MHC class I restricted tumor antigens with an artificial tumor antigen. A primary tumor is resected from the patient and a population of tumor cells are cultured in vitro. These cultured tumor cells are loaded with an artificial target antigen. The loaded tumor cells are inactivated and introduced into the patient either simultaneous or subsequent to a direct immunization of the patient with the same or substantially the same artificial target antigen. This method of coupled host immunization promotes a tumor specific cytotoxic T lymphocyte (CTL) immune response against multiple, undefined natural tumor antigens expressed on the unmodified tumor cell surface.

Abstract: Methods for preparing low free resorcinol resins are disclosed. These methods generally comprise reacting a resin with an aromatic olefinic compound; suitable resins include one or more resins selected from the group consisting of a dihydric phenol, a polyhydric phenol, a dihydric phenolic novolak resin and a polyhydric phenolic novolak resin; the addition product of at least one of these resins and at least one compound selected from the group consisting of a monooxirane compound and a polyoxirane compound; and a phenol or alkyl or aralkyl substituted mono- or dihydric phenol modified form of these resins. The resins produced by this method are also disclosed, as are rubber compositions utilizing the resin produced by this method.

Abstract: Pyrrolo?2,3-d!pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness are disclosed.

Abstract: Methods for preparing low free resorcinol resins are disclosed. These methods generally comprise reacting a resin with an aromatic olefinic compound; suitable resins include one or more resins selected from the group consisting of a dihydric phenol, a polyhydric phenol, a dihydric phenolic novolak resin and a polyhydric phenolic novolak resin; the addition product of at least one of these resins and at least one compound selected from the group consisting of a monooxirane compound and a polyoxirane compound; and a phenol or alkyl or aralkyl substituted mono- or dihydric phenol modified form of these resins. The resins produced by this method are also disclosed, as are rubber compositions utilizing the resin produced by this method.

Abstract: Novel sensor devices composed of a crystalline colloidal array (CCA) polymerized in a hydrogel are disclosed. The hydrogels are characterized as being capable of shrinking and swelling in response to specific stimuli applied thereto. As the hydrogels shrink or swell, the lattice structure of the CCA embedded therein changes, thereby changing the wavelength of light diffracted by the CCA. Thus by monitoring the change in diffracted wavelength, the concentration of a stimulus is determined. The gels can be modified to sense numerous different stimuli. The sensor devices are specific in that they are modified to react with only one species or family of species. These sensors have various applications in areas including, for example, environmental and chemical systems, chemomechanical systems, sensor devices and medical diagnostic tools. Various methods for making and using these devices are also disclosed.